Multicenter Polish Study on the Use of Bromocriptine in Peripartum Cardiomyopathy

Team

dr n. med. Karolina Kryczka

Project leader

Project value
Project value
Value of the Funding

Funding:

The project is funded by:
Medical Research Agency

Competition: ABM/2020/1
Project Number:
2020/ABM/01/00080

Project Name:

Multicenter Polish Study on the Use of Bromocriptine in Peripartum Cardiomyopathy. New Biomarkers in Early Diagnosis of Peripartum Cardiomyopathy (PeriPartum CardioMyopathy) PolBroM-PPCM

Project Description:

Peripartum cardiomyopathy (PPCM) is a life-threatening disease with reduced left ventricular ejection fraction (LVEF) <45%, occurring at the end of pregnancy or in the first months after delivery in women without prior heart disease. In Poland, there is a lack of precise data regarding PPCM. About 50% of patients recover, and in half, heart failure persists or progresses. Late diagnoses, related to the lack of validated, PPCM-specific biomarkers, worsen the prognosis. The 16 kDa form of prolactin (PRL), resulting from 23 kDa PRL due to excessive oxidative stress, plays a significant role in the development of PPCM. Bromocriptine, inhibiting the secretion of PRL from the pituitary, increases the degree of improvement in LVEF. An 8-week treatment can increase the number of full recoveries. Clinical cases indicate that further extension of treatment can additionally improve the prognosis.

The main objectives of the project are to assess the increase in LVEF depending on the length of bromocriptine treatment, to identify biomarkers most strongly associated with the occurrence of PPCM, response to treatment, or persistence of severe heart failure, to develop a widely available method for determining 16 kDa PRL, and to assess new mutations associated with PPCM. We expect to achieve an increase in the percentage of full recoveries of LVEF ≥50% in the case of extended bromocriptine treatment, to develop a new method for determining 16 kDa PRL, to establish a biomarker profile that can accelerate PPCM diagnostics and predict prognosis and response to treatment. We expect to understand the genetic basis of PPCM.

The study is funded by the state budget from the Medical Research Agency, Poland, Project Number: 2020/ABM/01/00080

logo Medical Research Agency